Maxim raised the firm’s price target on Sellas Life Sciences (SLS) to $7 from $4 and keeps a Buy rating on the shares. Shares have risen about 90% year-to-date as the company continues to execute across its Acute Myeloid Leukemia, or AML, programs, the analyst tells investors in a research note. Maxim further cites the company’s galinpepimut-S in Phase 3 and yesterday’s positive SLS009 data hitting all its endpoints, adding that its higher price target factors in SLS009 in first-line AML as a potential triplet combination with venetoclax/azacitidine.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLS:
- Sellas Life Sciences meets all primary endpoints in Phase 2 trial of SLS009
- Sellas Life Sciences appoints Linghua Wang to Scientific Advisory Board
- Largest borrow rate increases among liquid names
- Sellas Life Sciences to be added to Russell 3000, Russell 2000 indexes
- SELLAS Life Sciences Holds Annual Stockholders Meeting